Merck & Co., Inc. Stock

Equities

MRK

US58933Y1055

Pharmaceuticals

Market Closed - Nyse 04:00:02 2024-07-05 pm EDT 5-day change 1st Jan Change
126.4 USD +0.48% Intraday chart for Merck & Co., Inc. +2.14% +15.99%
Sales 2024 * 64.17B Sales 2025 * 68.64B Capitalization 320B
Net income 2024 * 19.51B Net income 2025 * 22.25B EV / Sales 2024 * 5.28 x
Net Debt 2024 * 18.6B Net Debt 2025 * 7.28B EV / Sales 2025 * 4.77 x
P/E ratio 2024 *
16.3 x
P/E ratio 2025 *
14.1 x
Employees 71,000
Yield 2024 *
2.45%
Yield 2025 *
2.59%
Free-Float 70.77%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.48%
1 week+2.14%
Current month+2.14%
1 month-3.23%
3 months-1.20%
6 months+7.87%
Current year+15.99%
More quotes
1 week
124.91
Extreme 124.91
128.24
1 month
120.87
Extreme 120.87
134.63
Current year
109.16
Extreme 109.16
134.63
1 year
99.14
Extreme 99.14
134.63
3 years
70.89
Extreme 70.89
134.63
5 years
65.25
Extreme 65.25
134.63
10 years
45.69
Extreme 45.69
134.63
More quotes
Managers TitleAgeSince
Chief Executive Officer 57 14-03-31
Director of Finance/CFO 55 89-12-31
Chief Tech/Sci/R&D Officer 55 20-07-31
Members of the board TitleAgeSince
Director/Board Member 63 07-11-26
Director/Board Member 67 15-08-31
Director/Board Member 69 18-02-28
More insiders
Date Price Change Volume
24-07-05 126.4 +0.48% 6,786,713
24-07-03 125.8 -1.46% 4,002,054
24-07-02 127.7 -0.14% 5,645,359
24-07-01 127.9 +3.31% 11,532,966

Delayed Quote Nyse, July 05, 2024 at 04:00 pm EDT

More quotes
Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows: - sale of pharmaceutical products (69.7%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.; - sale of vaccines (18%); - sale of animal health products (9.4%); - other (2.9%). Net sales are distributed geographically as follows: the United States (45.9%), Europe/Middle East/Africa (24.5%), China (8.8%), Japan (6.1%), Asia/Pacific (6.1%), Latin America (4.3%) and other (4.3%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
126.4 USD
Average target price
142.7 USD
Spread / Average Target
+12.84%
Consensus